Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study

Mayu Tochiya; Hisashi Makino; Tamiko Tamanaha; Miki Matsuo; Ai Hishida; Ryo Koezuka; Yoko Ohata; Tsutomu Tomita; Choel Son; Yoshihiro Miyamoto; Satoshi Yasuda; Kiminori Hosoda

doi:10.1111/jdi.13122

Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study

Mayu Tochiya, Hisashi Makino, Tamiko Tamanaha, Miki Matsuo, Ai Hishida, Ryo Koezuka, Yoko Ohata, Tsutomu Tomita, Choel Son, Yoshihiro Miyamoto, Satoshi Yasuda, Kiminori Hosoda

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Recent studies have shown that sodium–glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood. In the present study, we evaluated the effect of treatment with tofogliflozin for 6 months on cardiac and vascular endothelial function in 26 patients with type 2 diabetes and heart diseases. Tofogliflozin treatment significantly decreased left ventricular end-diastolic dimensions and significantly increased flow-mediated vasodilation. Although E/e′ did not significantly change after treatment, the decrease observed in the E/e′ ratio was significantly correlated with the increase in acetoacetic acid and 3-hydroxybutyrate levels. These results suggest that sodium–glucose cotransporter 2 inhibitor might improve left ventricular dilatation and vascular endothelial function in patients with type 2 diabetes. Furthermore, it is suggested that the elevation of ketone bodies induced by sodium–glucose cotransporter 2 inhibitors might contribute to a protective effect in left ventricular diastolic dysfunction.

Original language	English
Pages (from-to)	400-404
Number of pages	5
Journal	Journal of Diabetes Investigation
Volume	11
Issue number	2
DOIs	https://doi.org/10.1111/jdi.13122
Publication status	Published - 2020 Mar 1
Externally published	Yes

Keywords

Ketone body
Left ventricular diastolic function
Sodium–glucose cotransporter 2 inhibitor

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jdi.13122

Cite this

Tochiya, M., Makino, H., Tamanaha, T., Matsuo, M., Hishida, A., Koezuka, R., Ohata, Y., Tomita, T., Son, C., Miyamoto, Y., Yasuda, S., & Hosoda, K. (2020). Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study. Journal of Diabetes Investigation, 11(2), 400-404. https://doi.org/10.1111/jdi.13122

Tochiya, M, Makino, H, Tamanaha, T, Matsuo, M, Hishida, A, Koezuka, R, Ohata, Y, Tomita, T, Son, C, Miyamoto, Y, Yasuda, S & Hosoda, K 2020, 'Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study', Journal of Diabetes Investigation, vol. 11, no. 2, pp. 400-404. https://doi.org/10.1111/jdi.13122

@article{56a14d4aad6e446086e22c7b845f9be7,

title = "Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study",

abstract = "Recent studies have shown that sodium–glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood. In the present study, we evaluated the effect of treatment with tofogliflozin for 6 months on cardiac and vascular endothelial function in 26 patients with type 2 diabetes and heart diseases. Tofogliflozin treatment significantly decreased left ventricular end-diastolic dimensions and significantly increased flow-mediated vasodilation. Although E/e′ did not significantly change after treatment, the decrease observed in the E/e′ ratio was significantly correlated with the increase in acetoacetic acid and 3-hydroxybutyrate levels. These results suggest that sodium–glucose cotransporter 2 inhibitor might improve left ventricular dilatation and vascular endothelial function in patients with type 2 diabetes. Furthermore, it is suggested that the elevation of ketone bodies induced by sodium–glucose cotransporter 2 inhibitors might contribute to a protective effect in left ventricular diastolic dysfunction.",

keywords = "Ketone body, Left ventricular diastolic function, Sodium–glucose cotransporter 2 inhibitor",

author = "Mayu Tochiya and Hisashi Makino and Tamiko Tamanaha and Miki Matsuo and Ai Hishida and Ryo Koezuka and Yoko Ohata and Tsutomu Tomita and Choel Son and Yoshihiro Miyamoto and Satoshi Yasuda and Kiminori Hosoda",

note = "Funding Information: This study was funded by the Japanese Circulation Foundation. Publisher Copyright: {\textcopyright} 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd",

year = "2020",

month = mar,

day = "1",

doi = "10.1111/jdi.13122",

language = "English",

volume = "11",

pages = "400--404",

journal = "Journal of Diabetes Investigation",

issn = "2040-1116",

publisher = "Blackwell Publishing Asia Pty Ltd",

number = "2",

}

TY - JOUR

T1 - Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases

T2 - A pilot study

AU - Tochiya, Mayu

AU - Makino, Hisashi

AU - Tamanaha, Tamiko

AU - Matsuo, Miki

AU - Hishida, Ai

AU - Koezuka, Ryo

AU - Ohata, Yoko

AU - Tomita, Tsutomu

AU - Son, Choel

AU - Miyamoto, Yoshihiro

AU - Yasuda, Satoshi

AU - Hosoda, Kiminori

N1 - Funding Information: This study was funded by the Japanese Circulation Foundation. Publisher Copyright: © 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Recent studies have shown that sodium–glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood. In the present study, we evaluated the effect of treatment with tofogliflozin for 6 months on cardiac and vascular endothelial function in 26 patients with type 2 diabetes and heart diseases. Tofogliflozin treatment significantly decreased left ventricular end-diastolic dimensions and significantly increased flow-mediated vasodilation. Although E/e′ did not significantly change after treatment, the decrease observed in the E/e′ ratio was significantly correlated with the increase in acetoacetic acid and 3-hydroxybutyrate levels. These results suggest that sodium–glucose cotransporter 2 inhibitor might improve left ventricular dilatation and vascular endothelial function in patients with type 2 diabetes. Furthermore, it is suggested that the elevation of ketone bodies induced by sodium–glucose cotransporter 2 inhibitors might contribute to a protective effect in left ventricular diastolic dysfunction.

AB - Recent studies have shown that sodium–glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood. In the present study, we evaluated the effect of treatment with tofogliflozin for 6 months on cardiac and vascular endothelial function in 26 patients with type 2 diabetes and heart diseases. Tofogliflozin treatment significantly decreased left ventricular end-diastolic dimensions and significantly increased flow-mediated vasodilation. Although E/e′ did not significantly change after treatment, the decrease observed in the E/e′ ratio was significantly correlated with the increase in acetoacetic acid and 3-hydroxybutyrate levels. These results suggest that sodium–glucose cotransporter 2 inhibitor might improve left ventricular dilatation and vascular endothelial function in patients with type 2 diabetes. Furthermore, it is suggested that the elevation of ketone bodies induced by sodium–glucose cotransporter 2 inhibitors might contribute to a protective effect in left ventricular diastolic dysfunction.

KW - Ketone body

KW - Left ventricular diastolic function

KW - Sodium–glucose cotransporter 2 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85070742283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070742283&partnerID=8YFLogxK

U2 - 10.1111/jdi.13122

DO - 10.1111/jdi.13122

M3 - Article

C2 - 31361403

AN - SCOPUS:85070742283

SN - 2040-1116

VL - 11

SP - 400

EP - 404

JO - Journal of Diabetes Investigation

JF - Journal of Diabetes Investigation

IS - 2

ER -